---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075707"
form_type: "8-K/A"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:46:20.314807+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M

## Summary
- Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.
- Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.
- R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.
- VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.
- Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs.

## SEC filing metadata
- accession: 0001104659-25-075707
- form_type: 8-K/A
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/0001104659-25-075707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/tm2523009d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075707
- JSON: https://secwatch.observer/filing/0001104659-25-075707.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.